Immunocodex
Boston, US · 1 known investors
Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
Founders & leadership
MC
Mark CarthyFounder and CEO
FJ
Francisco J. QuintanaScientific Founder
Investors · 1
Frequently asked questions
- What does Immunocodex do?
- Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
- Who founded Immunocodex?
- Immunocodex was founded by Mark Carthy, Francisco J. Quintana.
- Who are Immunocodex's investors?
- Immunocodex's investors include Pfizer Venture Investments.
- Where is Immunocodex headquartered?
- Immunocodex is headquartered in Boston, US.